Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2022 | Biomarkers of delirium incidence and severity

Sharon K. Inouye, MD, MPH, Hebrew SeniorLife / Havard Medical School, Boston, MA, shares an overview of current investigations into biomarkers for delirium. Even after its resolution, delirium can be associated with prolonged hospital stay, loss of independence, reduced quality of life, cognitive decline, and increased mortality. Additionally, both delirium duration and delirium severity are associated with adverse patient outcomes, but there are currently no established diagnostic or prognostic biomarkers. Identifying markers capable of predicting risk of delirium, delirium duration, and delirium severity may provide mechanistic insights, as well as aiding in prevention and management. Several Amyloid-Tau-Neurodegeneration (ATN) biomarkers are currently under investigation. In particular, total tau (tTau), phosphorylated tau (pTau), and neurofilament light (NfL) levels in the cerebrospinal fluid (CSF) have been shown to associate with delirium incidence and severity. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.